201
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase I study of thymoglobulin for relapsed or refractory multiple myeloma

, , , , &
Pages 453-455 | Received 17 Mar 2015, Accepted 03 May 2015, Published online: 19 Jun 2015

References

  • Kumar S, Timm M, Kimlinger T, et al. Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) has in vitro activity in multiple myeloma. Blood 2005;106:5190.
  • Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507–1515.
  • Bensinger WI, et al. Antithymocyte globulin in treating patients undergoing stem cell transplant for multiple myeloma. ClinicalTrials.gov website; 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00378768?term = NCT00378768&rank = 1. Accessed December 12, 2014.
  • Kumar SK, et al. Anti-thymocyte globulin and melphalan in treating patients with relapsed multiple myeloma. ClinicalTrials.gov website; 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00635024?term = NCT00635024&rank = 1. Accessed December 12, 2014.
  • Stevens RV, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008;85: 1391–1399.
  • Remberger M, Ringdén O, Hägglund H, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transpl 2013;27: 368–374.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.